Prestige Consumer Healthcare Inc (N:PBH)
Business Focus: Pharmaceuticals
| Sector: Healthcare | Industry: Pharmaceuticals |
| See Regulatory Filings on SEC | |
| Company Contact | |
| Address: | 660 White Plains Rd TARRYTOWN NY 10591-5139 |
| Tel: | N/A |
| Website: | https://www.prestigebrands.com |
| IR: | See website |
| Key People | ||
| Ronald M. Lombardi Chairman of the Board, President, Chief Executive Officer | Christine Sacco Chief Financial Officer | Adel Mekhail Executive Vice President - Marketing & Sales |
| William C. P'Pool Senior Vice President, General Counsel, Corporate Secretary | Jeffrey Zerillo Senior Vice President - Operations | |
| Business Overview |
| Prestige Consumer Healthcare Inc. is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club and e-commerce stores in North America (the United States and Canada) and in Australia and certain other international markets. The Company operates through two segments: North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands include Monistat and Summer's Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux's Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others. |
| Financial Overview |
| For the nine months ended 31 December 2023, Prestige Consumer Healthcare Inc revenues increased 1% to $848.4M. Net income increased 1% to $159.9M. Revenues reflect North American OTC Healthcare-Eye & Ear Care segment increase of 8% to $117.7M, North American OTC Healthcare-Dermatologicals segment increase of 5% to $94.3M, International OTC Healthcare-Women's Health segment increase of 25% to $17.2M. |
| Employees: | 560 as of Mar 31, 2023 |
| Reporting Currency: | U.S. Dollars |
| Enterprise value: | $4,701M as of Dec 31, 2023 |
| Annual revenue (TTM): | $1,134M as of Dec 31, 2023 |
| EBITDA (TTM): | $380.19M as of Dec 31, 2023 |
| Net annual income (TTM): | -$80.67M as of Dec 31, 2023 |
| Free cash flow (TTM): | $232.04M as of Dec 31, 2023 |
| Net Debt Last Fiscal Year: | $1,138M as of Dec 31, 2023 |
| Shares outstanding: | 49,649,288 as of Feb 2, 2024 |
| Index Membership: | S&P 600 Small Cap |
| TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization | |
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.